VivoSeq
Other

Pathophysiology

0

Pipeline Programs

5

Active Trials

0

Companies Involved

Pathophysiology is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

8/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

12

clinical trials

Completed6 · 50%
Recruiting3 · 25%
Active, not recruiting1 · 8%
Not yet recruiting1 · 8%
Withdrawn1 · 8%

Trial Activity

12 trials

Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology
Active, not recruiting··Phase 2·NCT04451837·200 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)